CALCIMAR SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

CALCITONIN (SALMON SYNTHETIC)

Доступна с:

SANOFI-AVENTIS CANADA INC

код АТС:

H05BA01

ИНН (Международная Имя):

CALCITONIN (SALMON SYNTHETIC)

дозировка:

200UNIT

Фармацевтическая форма:

SOLUTION

состав:

CALCITONIN (SALMON SYNTHETIC) 200UNIT

Администрация маршрут:

INTRAMUSCULAR

Штук в упаковке:

2ML

Тип рецепта:

Prescription

Терапевтические области:

PARATHYROID AND ANTIPARATHYROID AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0111011001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2006-05-08

Характеристики продукта

1
PRODUCT MONOGRAPH
PR
CALCIMAR
®
Synthetic Salmon Calcitonin
Solution, 200 IU / mL
Intramuscular or Subcutaneous Injection
Calcium Regulator
sanofi-aventis Canada Inc
2905 Place Louis-R.-Renaud
Laval, Quebec, H7V 0A3
Date of Revision:
June 3, 2020
Submission Control No.: 230132
2
NAME OF DRUG
CALCIMAR
®
(Calcitonin-Salmon)
THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION
Synthetic Salmon Calcitonin
ACTIONS
CALCIMAR
participates in the regulation of the homeostasis of calcium by acting
primarily on the
bone; in Paget's disease presumably by an initial blocking effect on
accelerated bone resorption.
The rate of bone turnover appears to be decreased.
CALCIMAR participates in the regulation of urinary excretion of
phosphate and calcium.
Administration of CALCIMAR decreases the volume and acidity of the
gastric juice and decreases
the volume as well as trypsin and amylase content of the pancreatic
juice.
(For further details see Clinical Pharmacology section).
INDICATIONS
1.
Paget's Disease:
Treatment of symptomatic Paget's disease, only in patients who do not
respond to alternative
treatments or for whom such treatments are not suitable.
2.
Hypercalcemia:
Early treatment of hypercalcemic emergencies, along with other
appropriate agents, when a
rapid decrease in serum calcium is required, until more specific
treatment of the underlying
disease can be accomplished. It may also be added to existing
therapeutic regimens for
hypercalcemia such as intravenous fluids and furosemide, oral
phosphate or corticosteroids, or
other agents. Calcitonin may be used in patients with azotemia and
those with limited cardiac
reserve in whom intravenous fluids may be contraindicated.
Due to evidence of an increased risk of malignancies with the long
term calcitonin use, the
treatment duration should be limited to the shortest period of time
possible and using the minimum
effective dose.
3
CONTRAINDICATIONS
Patients who are hypersensitive to CALCIMAR or to any ingredient in
the formulation or
component of the container. For a complete lis